89bio, Inc.

NASDAQ•ETNB

CEO: Mr. Rohan Palekar

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2019-11-11

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Contact Information

142 Sansome Street, Second Floor, San Francisco, CA, 94104, United States

415-432-9270

www.89bio.com

Market Cap

$2.20B

P/E (TTM)

-5.2

17.9

Dividend Yield

52W High

$15.06

52W Low

$4.16

52W Range

98%

Rank70Top 99.2%

1.1

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 1.1 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q2 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.71+47.92%

4-Quarter Trend

FCF

-$100.43M+64.19%

4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

R&D Spending Rises Sharply Research and development expenses 168.3M USD for six months, up 82.4%, reflecting progression of Phase 3 ENLIGHTEN clinical trials.

Substantial Capital Raise Completed Net cash provided by financing 289.6M USD for six months, driven by 269.9M USD public offering and ATM sales.

Liquidity Position Strengthened Cash, equivalents, marketable securities 561.2M USD as of June 30, 2025, expected to fund operations for at least one year.

Risk Factors

Operating Losses Accelerate Significantly Net loss 182.8M USD for six months, up 83.4%; accumulated deficit reached 1.007B USD, requiring substantial future capital.

Clinical Trial Enrollment Challenges ENLIGHTEN-Fibrosis trial experiencing higher screen failures, potentially delaying expected topline histology data reporting timeline.

Israeli Tax Liability Risk Formal assessment order received from ITA asserting $26.0M tax liability plus $3.9M penalties; ultimate resolution uncertain.

Outlook

SHTG Topline Data Expected Q1 2026 Expect to report topline data from the ENTRUST Phase 3 SHTG trial in the first quarter of 2026, following study completion.

MASH Phase 3 Data Milestones ENLIGHTEN-Fibrosis histology topline data anticipated H1 2027; ENLIGHTEN-Cirrhosis data expected in 2028 for F4 patients.

ATM Facility Remaining Capacity Approximately $82.8M remains available for future common stock sales under the 2023 ATM Facility for liquidity management.

Peer Comparison

Revenue (TTM)

GLPG

$1.26B

+303.5%

TVTX

$490.73M

+110.5%

RCUS

$247.00M

-4.3%

Gross Margin (Latest Quarter)

LQDA

101.7%

+29.3pp

AGIO

96.9%

-4.3pp

BEAM

95.0%

-471.3pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
IBRX	$8.63B	-23.6	64.3%	175.0%
COGT	$5.52B	-7.0	-100.2%	27.0%
DNLI	$3.26B	-7.0	-50.1%	3.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data